Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuyan Zhou

Showing results (41-50 of 52) with videos related to

Pageof 6
Sort By:
Cancer Letters|November 27, 2024
TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancerMuhammad Jameel Mughal, Yi Zhang, Zhuqing Li, et al.
Nature Communications|October 21, 2025
And-1 coordinates with polymerase δ to regulate nucleotide excision repair and UVB-induced skin tumorigenesisShuyan Zhou, Yi Zhang, Zongzhu Li, et al.
Acta Biomaterialia|March 24, 2018
Scalable and cleavable polysaccharide nanocarriers for the delivery of chemotherapy drugsHao Wang, Tingting Dai, Shengli Li, et al.
Bioresource Technology|November 27, 2024
Effect of inoculated sludge concentration on start-up of anammox reactor: Nitrogen removal performance and metabolic pathwaysQian Guo, Xiang Chen, Hui Gong, et al.
Journal of Medicinal Chemistry|January 24, 2023
Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian CancerQiangsheng Zhang, Xinyi Chen, Jiaying Cao, et al.
Journal of Medicinal Chemistry|February 19, 2021
Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2Zhihao Liu, Xi Hu, Qiwei Wang, et al.
Journal of Medicinal Chemistry|November 30, 2022
Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of CancerGuoquan Wan, Zhanzhan Feng, Qiangsheng Zhang, et al.
Research Square|October 27, 2023
<i>O</i>-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancerWenge Zhu, Y I Zhang, Shuyan Zhou, et al.
Journal of Medicinal Chemistry|May 19, 2025
Discovery of a Potent FLT3 Inhibitor (<i>E</i>)-4-(3-(3-Fluoro-4-(morpholinomethyl)styryl)-1<i>H</i>-indazol-6-yl)pyridin-2-amine for the Treatment of Acute Myeloid Leukemia with Multiple FLT3 MutationsZhihao Liu, Ying Xu, Wei Wei, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 3, 2013
A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signallingYuqing Liu, Zhuo Wang, Jianing Wang, et al.
Pageof 6

Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Cancer Letters|November 27, 2024
TFAP2C-DDR1 axis regulates resistance to CDK4/6 inhibitor in breast cancerMuhammad Jameel Mughal, Yi Zhang, Zhuqing Li, et al.
Nature Communications|October 21, 2025
And-1 coordinates with polymerase δ to regulate nucleotide excision repair and UVB-induced skin tumorigenesisShuyan Zhou, Yi Zhang, Zongzhu Li, et al.
Acta Biomaterialia|March 24, 2018
Scalable and cleavable polysaccharide nanocarriers for the delivery of chemotherapy drugsHao Wang, Tingting Dai, Shengli Li, et al.
Bioresource Technology|November 27, 2024
Effect of inoculated sludge concentration on start-up of anammox reactor: Nitrogen removal performance and metabolic pathwaysQian Guo, Xiang Chen, Hui Gong, et al.
Journal of Medicinal Chemistry|January 24, 2023
Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian CancerQiangsheng Zhang, Xinyi Chen, Jiaying Cao, et al.
Journal of Medicinal Chemistry|February 19, 2021
Design and Synthesis of EZH2-Based PROTACs to Degrade the PRC2 Complex for Targeting the Noncatalytic Activity of EZH2Zhihao Liu, Xi Hu, Qiwei Wang, et al.
Journal of Medicinal Chemistry|November 30, 2022
Design and Synthesis of Fibroblast Growth Factor Receptor (FGFR) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of CancerGuoquan Wan, Zhanzhan Feng, Qiangsheng Zhang, et al.
Research Square|October 27, 2023
<i>O</i>-GlcNAcylation of MITF regulates its activity and CDK4/6 inhibitor resistance in breast cancerWenge Zhu, Y I Zhang, Shuyan Zhou, et al.
Journal of Medicinal Chemistry|May 19, 2025
Discovery of a Potent FLT3 Inhibitor (<i>E</i>)-4-(3-(3-Fluoro-4-(morpholinomethyl)styryl)-1<i>H</i>-indazol-6-yl)pyridin-2-amine for the Treatment of Acute Myeloid Leukemia with Multiple FLT3 MutationsZhihao Liu, Ying Xu, Wei Wei, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|January 3, 2013
A histone deacetylase inhibitor, largazole, decreases liver fibrosis and angiogenesis by inhibiting transforming growth factor-β and vascular endothelial growth factor signallingYuqing Liu, Zhuo Wang, Jianing Wang, et al.
Pageof 6